Mediterranean vs. Low-Fat Diet: The CVD Evidence Is Messier

The comparison everyone thought was settled is not. Mediterranean diets beat low-fat diets on several cardiovascular risk markers, including total cholesterol, the cholesterol-to-HDL ratio, fasting insulin, blood glucose, leukocyte count, and BMI. But the longest head-to-head trial measuring major cardiovascular events found something less tidy: patients with established coronary disease had fewer events when they adhered closely to either diet.

That does not make the Mediterranean diet a mirage. It has the better record for the numbers clinicians routinely measure, and extra-virgin olive oil appears to improve inflammatory and endothelial biomarkers beyond what a low-fat diet achieves. Yet better blood-panel results are surrogate outcomes. A lower cholesterol ratio is useful; it is not the same endpoint as fewer heart attacks, strokes, or cardiovascular deaths.

What the head-to-head evidence actually shows

A 2026 systematic review by Mylavarapu et al. examined 11 randomized controlled trials with 5,942 participants that directly compared Mediterranean and low-fat diets. Across those trials, the Mediterranean diet produced greater improvements in total cholesterol, the cholesterol-to-HDL ratio, fasting insulin, blood glucose, leukocyte count, and BMI.

This is meaningful, but it has boundaries. The review's advantage for the Mediterranean diet was driven mainly by intermediate markers, not by a pooled hard-endpoint result. The publication does not provide a single confidence interval or pooled effect estimate for the comparisons cited here, so the size of each advantage cannot be judged from its abstract alone. "Significant" tells readers that a result met the study's statistical threshold; it does not tell them whether the difference was large enough to change an individual patient's prognosis.

The biological pattern is reasonably coherent. A 2025 meta-analysis by Pourrajab et al. found that a Mediterranean diet supplemented with olive oil reduced circulating inflammatory markers and endothelial-dysfunction indexes more than a low-fat diet in clinical controlled trials. Endothelial dysfunction and chronic inflammation are relevant to atherosclerosis, so these findings make the biomarker pattern more plausible. They still do not prove that olive-oil polyphenols, rather than the full dietary pattern or another behavioral change, caused fewer clinical events.

The seven-year trial changes the practical question

The CORDIOPREV trial provides the most important counterweight. In Spain, 1,002 patients with coronary heart disease were randomized to a Mediterranean diet or a low-fat diet and followed for seven years. In a 2026 analysis, Delgado-Lista et al. reported that greater adherence to either assigned pattern was associated with lower incidence of major adverse cardiovascular events. The association was directionally similar in both groups; the study did not identify diet assignment as the variable that separated hard-event benefit.

That endpoint matters more than a fasting lab value. CORDIOPREV assessed major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke. It did not show that the two diets produce identical biology, nor does it erase the Mediterranean diet's biomarker advantages. It does show that a well-followed low-fat diet can deliver comparable protection against major events in secondary prevention over a clinically relevant period.

Why might the results differ from shorter biomarker trials? Duration is one reason. Early dietary trials capture changes in weight, glucose, lipids, and inflammatory markers before adherence has had years to drift. A seven-year trial captures the less glamorous variable that decides whether a diet survives ordinary life: whether people keep eating it. The trials also differ in populations, endpoints, intervention details, and support. Pooling them can summarize a literature, but it cannot make those differences disappear.

Adherence is part of the treatment

Evidence from PREDIMED-Plus reinforces the point. In a longitudinal analysis from a large randomized trial, Martínez-González et al. found that yearly attained Mediterranean-diet adherence predicted lower diabetes incidence independently of baseline risk. Participants with sustained high adherence to an extra-virgin-olive-oil-supplemented Mediterranean diet had a 40% relative reduction in diabetes risk. The document does not provide an absolute risk difference or confidence interval for that figure, so it should not be converted into a promise of individual benefit.

This analysis does not prove that self-reported adherence caused every difference; people who adhere more closely may differ in other health behaviors. Still, it fits the CORDIOPREV result: dietary assignment starts the intervention, but sustained dietary behavior determines much of its real-world effect.

There are additional signs that Mediterranean and low-fat diets may diverge on outcomes beyond standard lipid panels. In the CORDIOPREV cohort, a long-term Mediterranean diet preserved kidney function better than the low-fat comparator among coronary heart disease patients in a 2022 randomized trial report. That kidney-function analysis is relevant to cardiorenal health, but it is not evidence of fewer cardiovascular events. Separately, a 2025 CORDIOPREV analysis found more recurrent cardiovascular events among participants reporting at least eight hours of sleep than among those reporting more than six but fewer than eight hours; the Mediterranean intervention partially modified that association. The sleep analysis is observational within the trial and cannot establish that changing sleep duration prevents recurrence.

Mechanisms deserve restraint

Platelets are one proposed pathway. A PREDIMED-family randomized trial reported that the Mediterranean diet maintained platelet counts within a healthy range and reduced thrombocytopenia-related mortality risk. Hernáez et al. also discussed earlier PREDIMED analyses linking the dietary pattern with lower circulating prothrombotic microvesicles.

The microvesicle story remains a hypothesis with biological credibility, not settled mechanism. No available head-to-head randomized trial measured microvesicle reduction as a prespecified primary endpoint with independently reportable effect sizes, confidence intervals, and p-values. Treating it as established would turn background rationale into proof.

Why the evidence does not travel perfectly

Most major direct comparisons came from Spain and enrolled adults at high cardiovascular risk. Food culture matters: olive oil, legumes, fish, and minimally processed meals are easier to sustain where they are ordinary rather than specialty groceries. No comparable long-duration head-to-head trial in North America, Asia, Northern Europe, or sub-Saharan Africa is identified here. A finding in Southern European secondary prevention should not be assumed to have the same size in every food environment.

The PREDIMED trial family also carries a known methodological complication: investigators republished the foundational trial after identifying site-level departures from randomization procedures. The republication tested whether results held after accounting for the affected observations, but reviews containing PREDIMED-derived studies inherit that history.

Adherence measurement adds another uncertainty. These studies commonly used the 14-item self-reported MEDAS questionnaire rather than objective measures such as urinary polyphenols or plasma fatty-acid profiles across all participants. People may overreport foods they know the study team favors. Since adherence appears to modify outcomes, imperfect measurement can blur or distort the comparison.

Results may also differ by metabolic phenotype. A 2025 meta-analysis in overweight and obese adults found heterogeneity in Mediterranean-diet effects across BMI categories. That finding limits claims that one average result applies uniformly across people with different metabolic risk profiles. A 2024 network meta-analysis of dietary interventions adds a broader reminder: several dietary patterns can improve cardiovascular outcomes, and the apparent ranking changes with the outcome measured. A Mediterranean diet is a strong option, not the only dietary pattern with evidence.

The useful verdict

Choose a Mediterranean-style diet if you want the best-supported option for improving lipid ratios, fasting insulin, glucose, inflammatory and endothelial markers, and BMI relative to a low-fat diet. Build it around extra-virgin olive oil, vegetables, legumes, oily fish, and fewer ultra-processed foods.

Do not mistake that conclusion for proof that Mediterranean eating prevents more heart attacks or strokes than every well-executed low-fat diet. The best long-term direct trial found that close adherence to either pattern tracked with fewer major cardiovascular events. For people deciding what to eat for years rather than for a six-week lab-panel makeover, the decisive question is practical: which evidence-based pattern can you follow consistently in your own kitchen, budget, culture, and schedule?